Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica, an R&D biopharmaceutical company, has announced that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has received approval from the health authorities in Belgium and Luxemburg.
Subscribe to our email newsletter
Subsequent to the recommendation for regulatory approval under the European decentralized procedure, Basilea received the marketing authorization for Toctino in Belgium and Luxemburg.
Following the regulatory approval of Toctino in Belgium and Luxemburg, Basilea will submit a pricing and reimbursement dossier to the country authorities. Toctino was developed by Basilea Pharmaceutica International.